PME March 2022: Medical Affairs Synergy, Cost-Effectiveness of Combination Therapies, and More

Medical affairs plays a critical role in synchronizing companies’ business and research efforts. This and more are covered in Pharmaceutical Market Europe’s latest issue (PME). Another article explores the promise and challenges of combination medicine and the barriers to access caused by reimbursors’ reticence to cover such treatment, ostensibly based on concerns of cost-effectiveness.

According to PME, “As Tanja [Podkonjak] explains, combination treatments are comprised of a ‘backbone’ treatment, often considered to be the existing standard of care, combined with a new ‘add-on’ treatment. She adds that, despite potentially delivering significant clinical benefits for patients with complex diseases, they often face cost-effectiveness barriers that result in a lack of patient access or reimbursement of these treatments.”

Read the entire issue by clicking here.

(Source: PME, March 2022)